Academy of Managed Care Pharmacy (AMCP)Molluscum Contagiosum: A Viral Skin Disease

Date & Time:

• Tuesday, July 11, 2023, 2-3 PM ET

Speaker:

• Gary Goldenberg, MD, Assistant Clinical Professor, Dermatology, Icahn School of Medicine at Mount Sinai Hospital, Chief Medical Officer, Verrica Pharmaceuticals Inc.

Webinar Description:

• This webinar will focus on VP-102, an investigational drug being reviewed by the FDA for the treatment of molluscum contagiosum. The safety and efficacy of VP-102 has not been established.
• The Company’s NDA for VP-102 was resubmitted to the FDA in January, 2023 and assigned a PDUFA goal date of July 23, 2023.
• The 505(b)(1) NDA was supported by positive results from two identical, double-blind, randomized Phase 3 trials (CAMP-1 and CAMP-2) that evaluated the safety and efficacy of VP-102 compared to vehicle in patients.

Dermatology Latest Posts

• First Cases of HIV Transmitted Through Cosmetic Needles Identified: CDCMay 3, 2024
• The Most Competitive Medical SpecialtiesApril 30, 2024
• Study Shows AI Improves Accuracy of Skin Cancer DiagnosesApril 22, 2024
• Central Cyanosis in Acquired MethemoglobinemiaApril 17, 2024

Did You Know?
Molluscum contagiosum affects approximately 6 million people in the US each year, predominantly children.